vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
vTv Therapeutics (Nasdaq: VTVT) granted 12,500 stock options to two non-executive employees as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
The options have a weighted average exercise price of $34.15, vest over 4 years, carry a 10-year term, and are issued under the 2026 Inducement Plan.
Positive
- None.
Negative
- None.
News Market Reaction – VTVT
In the Jul 6 session, VTVT declined 2.43%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Inducement option grant | Neutral | -0.2% | Small stock option inducement grant to a new employee under Nasdaq rules. |
| May 13 | Earnings report | Positive | +21.4% | Q1 2026 revenue and net income driven by licensing payments and strong cash. |
| May 08 | Inducement option grant | Neutral | -0.7% | Inducement stock options for non-executive employees under the 2026 plan. |
| May 07 | Conference participation | Neutral | -2.0% | Announcement of participation in May 2026 investor conferences and webcasts. |
| Apr 07 | Inducement option grant | Neutral | +0.6% | Grant of stock options to a non-executive employee under inducement plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent vTv headlines, including repeated inducement option grants and one strong earnings release, have generally coincided with modest, directionally consistent share-price reactions.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 12,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options that were granted have a weighted average exercise price of
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
